# MGNX catalysts: MACROGENICS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mgnx/catalysts

> MACROGENICS INC (MGNX) has 2 upcoming catalysts. The next is the lorigerlimab primary completion, July 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | MACROGENICS INC |
| Ticker | MGNX (Nasdaq) |
| SEC CIK | 1125345 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mgnx |

## Cash runway

Cash $49.0M as of 2026-09-30; quarterly burn $6.3M; about 23.2 months of runway at that rate (XBRL company facts, accession 0001125345-26-000073).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2022 | [TZIELD® (teplizumab) FDA approval](https://sec-api.dev/pdufa/teplizumab) | MGNX |  | completed, approved | "In November 2022, the U.S. FDA approved TZIELD (teplizumab-mzwv) to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D, which triggered a $60.0 million milestone payment to us." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1125345/000112534525000042/mgnx-20241231.htm)) |
| March 20, 2025 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "ROCKVILLE, MD., Mar 20, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534525000043/exhibit99-1earningspressre.htm)) |
| May 13, 2025 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "ROCKVILLE, MD., May 13, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534525000054/exhibit99-1earningspressre.htm)) |
| August 14, 2025 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534525000100/exhibit99-1earningspressre.htm)) |
| November 12, 2025 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534525000109/exhibit99-1earningspressre.htm)) |
| February 19, 2026 | [Lorigerlimab primary completion](https://sec-api.dev/pdufa/lorigerlimab) | MGNX |  | completed | "NCT05848011 (A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-19 (ACTUAL); Lead Sponsor MacroGenics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05848011)) |
| March 9, 2026 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000018/exhibit99-1earningspressre.htm)) |
| May 13, 2026 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000040/exhibit99-1earningspressre.htm)) |
| Q3 2026 | [MGC030 trial start](https://sec-api.dev/pdufa/mgc030) | MGNX |  | scheduled | "The Company plans to commence a Phase 1 dose escalation study in the third quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/exhibit99-1earningspressre.htm)) |
| August 13, 2026 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/exhibit99-1earningspressre.htm)) |
| October 23, 2026 | [MGC026 interim data readout](https://sec-api.dev/pdufa/mgc026) | MGNX |  | completed, positive | "ROCKVILLE, Md., October 23, 2026 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000066/a991pressreleasedatedoctob.htm)) |
| November 12, 2026 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000074/exhibit99-1earningspressre.htm)) |
| July 2027 | [Lorigerlimab primary completion](https://sec-api.dev/pdufa/lorigerlimab) | MGNX |  | scheduled | "NCT06730347 (A Study of Lorigerlimab in Participants With Advanced Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor MacroGenics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06730347)) |
| Jul to Oct 2027 | [Lorigerlimab topline data readout](https://sec-api.dev/pdufa/lorigerlimab) | MGNX |  | scheduled | "NCT06730347 (A Study of Lorigerlimab in Participants With Advanced Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor MacroGenics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06730347)) |

## Drugs

- [Lorigerlimab](https://sec-api.dev/pdufa/lorigerlimab): Androgen-Independent Prostatic Cancer, Platinum-resistant Ovarian Cancer
- [MGC026](https://sec-api.dev/pdufa/mgc026): cancer, today
- [MGC030](https://sec-api.dev/pdufa/mgc030): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mgnx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MGNX catalysts: MACROGENICS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mgnx/catalysts

```bibtex
@misc{secapidev_companies_mgnx_catalysts_20261116,
  title        = {MGNX catalysts: MACROGENICS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mgnx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mgnx_catalysts_20261116","title":"MGNX catalysts: MACROGENICS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mgnx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
